Blueprint Medicines Corporation (BPMC) News

BPMC will the uptrend resume

Why the drop today...the news release seems positive...anyone with Intel wish to educate fellow ihubbers!!!

Ziggy

BPMC buy 98.69

I decided to make a scan based on John Carter's TTM Squeeze indicator.



Here is the chart layout for Thinkorswim
http://tos.mx/wiwLksF




Here is the actual scanner that picked this stock
http://tos.mx/TPsL1CD



https://finance.yahoo.com/quote/BPMC/profile?p=BPMC

https://www.barchart.com/stocks/quotes/BPMC

https://finviz.com/quote.ashx?t=BPMC

https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=BPMC

https://stockcharts.com/c-sc/sc?chart=BPMC,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b

https://www.barchart.com/etfs-funds/quotes/BPMC/technical-chart?plot=CANDLE&volume=toBPMC&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=TREND&sym=BPMC&grid=1&height=500&studyheight=100&timeframe=2%20Months




normal chart









log chart









normal chart








log chart

Blueprint Medicines Corp.


Blueprint Medicines Corp . is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Avapritinib
Today is the date

Sold near EOD @ $59.60. Earnings pre-market tomorrow. Don't know the company that well and seems to have a mixed earnings record.

Good luck to longs.

BPMC

Back in @ $63.00. Chart not great.

BarChart cheat sheet:

Pivot Point 1st Resistance Point 65.67
65.43 50% Retracement From 4 Week High/Low
65.17 Price Crosses 18 Day Moving Average
64.70 Pivot Point
64.47 14-3 Day Raw Stochastic at 50%
64.05 38.2% Retracement From 4 Week Low
High 63.79 High
Previous Close 63.76 Previous Close
Last 63.11 Last
Pivot Point 1st Support Point 62.78
Low 62.69 Low
62.51 14-3 Day Raw Stochastic at 30%
62.46 3-10 Day MACD Oscillator Stalls
Pivot Point 2nd Support Point 61.81
________________________________________________
https://www.barchart.com/stocks/quotes/BPMC/cheat-sheet

BPMC

Out @ $67.80. Has moved nicely with biotech of late. Moving to greater resistance. Will be back.

BPMC

Back in @ $62 and $63. Still not low enough with the biotech self-off continuing (LABU is down 9%).

BPMC

Out @ $73.60. May buy back if it dips, but was sitting on ask to preserve profits.

BPMC

In at $68.50. Catalyst next week.

Analyst favorite:

Consensus Rating: Buy
Consensus Rating Score: 3.00
Ratings Breakdown:
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $87.1111
Price Target Upside: 22.55% upside
____________________________________________
https://www.marketbeat.com/stocks/NASDAQ/BPMC/

BPMC

BPMC 8-k filed, published proof of concept data:

http://ih.advfn.com/p.php?pid=nmona&article=77183488

http://ih.advfn.com/p.php?pid=nmona&article=77178297

More than doubled over the last year.

BPMC bullish 20.36

Nice action since the lockup

Blueprint Medicines Corp's (BPMC) Lock-Up Period Set To End on October 27th

CAMBRIDGE, Mass., April 29, 2015 /PRNewswire/ -- Blueprint Medicines today announced the pricing of its initial public offering of 8,145,834 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. In addition, Blueprint Medicines granted the underwriters a 30-day option to purchase up to an additional 1,221,874 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on April 30, 2015 under the ticker symbol "BPMC."

Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running managers for the offering. JMP Securities is acting as a co-manager for the offering. Wedbush PacGrow is also acting as a co-manager for the offering.

A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on April 29, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com, and from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (631) 274-2806, or by fax at (631) 254-7140.

Contact:
Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com

Media:
Beth Keshishian
inVentiv Health PR
212-229-8417
beth.keshishian@inventivhealth.com

SOURCE Blueprint Medicines

http://www.prnewswire.com/news-releases/blueprint-medicines-announces-pricing-of-initial-public-offering-300074756.html

Blueprint Medicines (BPMC) expects to raise $115 million in an initial public offering (IPO) on Thursday, April 30th. The company will be issuing 7,200,000 shares at a price of $15.00-$17.00 per share.

Blueprint Medicines has a market cap of $398 million.

Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines provided the following description of their company for its IPO: “We are a biopharmaceutical company focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. Our approach is to systematically and reproducibly identify kinases that are drivers of genomically defined diseases and to craft drug candidates with therapeutic windows that provide significant and durable clinical responses to patients. This integrated biology and chemistry approach enables us to drug known kinases that have been difficult to inhibit selectively and also identify, characterize and drug novel kinase targets.”.

Blueprint Medicines was founded in 2008 and has 60 employees. The company is located at 215 First Street, Cambridge, MA 02142,, US and can be reached via phone at (617) 374-7580 or on the web at www.blueprintmedicines.com.